Diabetes Care: Obstructive sleep apnea is a risk factor for cardiovascular and microvascular diseases in people with type 2 diabetes

In a recent study published in Diabetes Care, a leading journal of diabetes, researchers aimed to identify the risk of cardiovascular disease (CVD), microvascular complications and death in patients with type 2 diabetes who developed OSA compared to people with type 2 diabetes who did not have a diagnosis of obstructive sleep apnea (OSA)the cohort study, which matches age, gender, BMI and diabetes, used data from 1 January 2005 to 17 January 2018 in the UK Primary Care DatabaseThe study included people with type 2 diabetes over the age of 16The exposed participants were those who developed OSA after the diagnosis of diabetes; The results of the study were CVD complex events (ischemic heart disease (IHD), stroke/transient cerebral ischemic episodes (TIA), heart failure (HF), peripheral vascular disease (PVD), atrial fibrillation (AF), peripheral neuropathy (PN), diabetic-related foot disease (DFD), retinal disease, chronic kidney disease (CKD), and total cause mortalityThe researchers did the same for patients with OSA before the diagnosis of type 2 diabetes and diabetics without OSAthe study included a total of 3,667 exposed participants and 10,450 matching control participantsAdjusted ending risks such as the following: CVD composite event s1.54 (95% CI 1.32, 1.79), IHD 1.55 (1.26, 1.90), HF 1.67 (1.35, 2.06), stroke/TIA 1.57 (1.27, 1.94), PVD 1.10 (01.91) 1.32), AF at 1.53 (1.28, 1.83), PN at 1.32 (1.14, 1.51), DFD 1.42 (1.16, 1.74), retinal lesions at 0.99 (0.82, 1.21), CKD (3-5 periods) at 1.18 (1.02, 1.36), albumin urination is 1.11 (1.01, 1.22) and the whole cause mortality rate is 1.24 (1.10, 1.40)In the OSA queue, the results are similar, but no association is observedthus, there was an increase in CVD, AF, PN, DFD, CKD and all-cause deaths in patients with TYPE 2 with OSA compared to patients without OSAPeople with type 2 diabetes with OSA are at high risk and should be screened for OSA to prevent cardiovascular and microvascular complications